After years of litigation, AstraZeneca (AZN) agreed to pay $110 million to settle allegations of illegally marketing two best-selling drugs and, subsequently, causing the Texas Medicaid program to overpay for the medicines.

The company was accused of promoting its Seroquel antipsychotic for treating children and teenagers when the drug was not approved for that population, and paying kickbacks to two former state hospital doctors so they would prescribe the pill. AstraZeneca was also accused of marketing its Crestor cholesterol pill for unapproved uses and downplaying risk of diabetes in some patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy